Saggese G, Federico G, Barsanti S, Fiore L
Endocrine Unit, Division of Pediatrics, Department of Reproductive Medicine and Pediatrics, University of Pisa, Santa Chiara Hospital, Italy.
J Clin Endocrinol Metab. 2001 May;86(5):1900-4. doi: 10.1210/jcem.86.5.7439.
To assess whether delaying puberty may improve final height in GH-deficient children with a poor height prediction at early puberty, we studied 24 girls with isolated GH deficiency until they reached their final height, in a controlled trial. Patients were taking recombinant human GH (r-hGH) substitutive therapy from 2.1 +/- 0.5 yr (0.1 IU/kg.day sc) before entering the study, without showing any improvement in height prediction (149.6 +/- 2.9 vs.150.3 +/- 2.2 cm) on entering puberty. Fourteen girls agreed to add a GnRH agonist (GnRHa) to r-hGH, whereas the remaining 10 decided against it and served as controls. At the start of the study, girls treated with or without GnRHa had similar auxological characteristics (bone age, 10.9 +/- 0.6 vs. 10.7 +/- 1.3 yr; height SD score for chronological age, -1.87 +/- 0.3 vs. -1.82 +/- 0.2), including pubertal development. The GnRHa (long-acting D-Trp-6-GnRH) was given at 60 microg/kg im every 28 days for 1.9 +/- 0.9 yr, then patients continued the r-hGH at the same dosage (3.1 +/- 0.7 yr). At the end of the study, bone age was 16.2 +/- 0.3 yr in GnRHa-treated girls and 16.6 +/- 0.9 yr in controls. Bone maturation was significantly slower during GnRHa (1.4 +/- 0.2 yr), and height SD score for bone age improved (-0.31 +/- 0.3) in comparison with controls (2.6 +/- 0.4 yr and -1.35 +/- 0.3 SD score; P < 0.001 and P < 0.0001, respectively). As a result, girls given the combined therapy reached a final height higher than that of controls (height SD score, -0.39 +/- 0.5 vs. -1.45 +/- 0.2; P < 0.0001) and also higher than their midparental height (-1.1 +/- 0.5; P < 0.0005). Controls reached their midparental height. In conclusion, our results demonstrate that slowing pubertal development with the administration of GnRHa for a limited time may improve final height in GH-deficient girls selected because of a poor height prediction at early puberty.
为了评估延迟青春期是否可以改善青春期早期身高预测较差的生长激素缺乏儿童的最终身高,我们在一项对照试验中研究了24名孤立性生长激素缺乏的女孩,直至她们达到最终身高。患者在进入研究前从2.1±0.5岁起(0.1IU/kg·天,皮下注射)接受重组人生长激素(r-hGH)替代治疗,进入青春期时身高预测没有任何改善(149.6±2.9 vs.150.3±2.2cm)。14名女孩同意在r-hGH基础上加用促性腺激素释放激素激动剂(GnRHa),而其余10名女孩决定不加用,作为对照。在研究开始时,接受或未接受GnRHa治疗的女孩具有相似的体格学特征(骨龄,10.9±0.6 vs.10.7±1.3岁;按年龄计算的身高标准差评分,-1.87±0.3 vs.-1.82±0.2),包括青春期发育情况。GnRHa(长效D-Trp-6-GnRH)每28天以60μg/kg肌肉注射,共1.9±0.9年,然后患者继续以相同剂量接受r-hGH治疗(3.1±0.7年)。在研究结束时,接受GnRHa治疗的女孩骨龄为16.2±0.3岁,对照组为16.6±0.9岁。在使用GnRHa期间骨成熟明显较慢(1.4±0.2年),与对照组相比,按骨龄计算的身高标准差评分有所改善(-0.31±0.3)(分别为2.6±0.4年和-1.35±0.3标准差评分;P<0.001和P<0.0001)。结果,接受联合治疗的女孩达到的最终身高高于对照组(身高标准差评分,-0.39±0.5 vs.-1.45±0.2;P<0.0001),也高于她们的父母平均身高(-1.1±0.5;P<0.0005)。对照组达到了她们的父母平均身高。总之,我们的结果表明,在有限时间内使用GnRHa减缓青春期发育可能会改善因青春期早期身高预测较差而入选的生长激素缺乏女孩的最终身高。